A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis

Nail psoriasis is a difficult-to-treat manifestation of psoriatic disease affecting up to 80% of patients with psoriatic arthritis (PsA) and 40–60% of patients with plaque psoriasis (PsO). Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirkham, Bruce W., Egeberg, Alexander, Behrens, Frank, Pinter, Andreas, Merola, Joseph F., Holzkämper, Thorsten, Gallo, Gaia, Ng, Khai Jing, Bolce, Rebecca, Schuster, Christopher, Nash, Peter, Puig, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469116/
https://www.ncbi.nlm.nih.gov/pubmed/37400681
http://dx.doi.org/10.1007/s40744-023-00553-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469116/
https://www.ncbi.nlm.nih.gov/pubmed/37400681
http://dx.doi.org/10.1007/s40744-023-00553-1

Ejemplares similares